S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Nevada Could be the Source for America's Green Future (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Nevada Could be the Source for America's Green Future (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Lithium Could Be 2023's Next Big Surprise (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Nevada Could be the Source for America's Green Future (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Nevada Could be the Source for America's Green Future (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Lithium Could Be 2023's Next Big Surprise (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Nevada Could be the Source for America's Green Future (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Nevada Could be the Source for America's Green Future (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Lithium Could Be 2023's Next Big Surprise (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Nevada Could be the Source for America's Green Future (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Nevada Could be the Source for America's Green Future (Ad)
Roku And The 20% Rally That’s About To Start 
3 More Downgrades To Put On Your Buy List 
Lithium Could Be 2023's Next Big Surprise (Ad)
The Bottom Is In For McCormick & Company
Buffett's company owns nearly 24% of Occidental Petroleum
NASDAQ:RCKT

Rocket Pharmaceuticals - RCKT Competitors

$15.79
-0.85 (-5.11%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$15.79
$16.75
50-Day Range
$15.79
$22.60
52-Week Range
$7.57
$23.48
Volume
784,959 shs
Average Volume
1.07 million shs
Market Capitalization
$1.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.58

RCKT vs. RNA, KDNY, CVAC, CINC, TVTX, SNDX, AUPH, ARVN, VRNA, and DICE

Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Avidity Biosciences (RNA), Chinook Therapeutics (KDNY), CureVac (CVAC), CinCor Pharma (CINC), Travere Therapeutics (TVTX), Syndax Pharmaceuticals (SNDX), Aurinia Pharmaceuticals (AUPH), Arvinas (ARVN), Verona Pharma (VRNA), and DICE Therapeutics (DICE). These companies are all part of the "pharmaceutical preparations" industry.

Rocket Pharmaceuticals vs.

Avidity Biosciences (NASDAQ:RNA) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

Rocket Pharmaceuticals received 233 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 73.20% of users gave Rocket Pharmaceuticals an outperform vote while only 62.89% of users gave Avidity Biosciences an outperform vote.

CompanyUnderperformOutperform
Avidity BiosciencesOutperform Votes
122
62.89%
Underperform Votes
72
37.11%
Rocket PharmaceuticalsOutperform Votes
355
73.20%
Underperform Votes
130
26.80%

Avidity Biosciences currently has a consensus target price of $44.60, suggesting a potential upside of 122.00%. Rocket Pharmaceuticals has a consensus target price of $52.58, suggesting a potential upside of 233.02%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Avidity Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avidity Biosciences
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20
Rocket Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
3.00

Rocket Pharmaceuticals has a net margin of 0.00% compared to Avidity Biosciences' net margin of -1,886.33%. Avidity Biosciences' return on equity of -40.82% beat Rocket Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Avidity Biosciences -1,886.33% -40.82% -36.41%
Rocket Pharmaceuticals N/A -53.39% -47.69%

93.2% of Rocket Pharmaceuticals shares are owned by institutional investors. 6.6% of Avidity Biosciences shares are owned by company insiders. Comparatively, 33.7% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Rocket Pharmaceuticals had 13 more articles in the media than Avidity Biosciences. MarketBeat recorded 15 mentions for Rocket Pharmaceuticals and 2 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 1.27 beat Rocket Pharmaceuticals' score of 0.12 indicating that Avidity Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Avidity Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rocket Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Avidity Biosciences has higher revenue and earnings than Rocket Pharmaceuticals. Avidity Biosciences is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avidity Biosciences$9.22 million154.29-$173.99 million-$3.33-6.03
Rocket PharmaceuticalsN/AN/A-$221.86 million-$3.29-4.80

Summary

Rocket Pharmaceuticals beats Avidity Biosciences on 10 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCKT vs. The Competition

MetricRocket PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.32B$5.66B$4.39B$5.82B
Dividend YieldN/A2.62%2.42%4.53%
P/E Ratio-4.8010.27123.1215.61
Price / SalesN/A282.603,461.5658.92
Price / CashN/A18.0119.7822.50
Price / Book2.444.204.515.04
Net Income-$221.86M$187.05M$115.21M$191.41M
7 Day Performance-11.64%-1.99%-1.80%-1.01%
1 Month Performance-17.80%-9.55%-7.80%-6.46%
1 Year Performance3.27%-10.34%-14.51%-17.46%

Rocket Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNA
Avidity Biosciences
1.4655 of 5 stars
$19.56
-5.3%
$44.60
+128.0%
+15.9%$1.39B$9.22M-5.87125
KDNY
Chinook Therapeutics
2.4854 of 5 stars
$21.53
-2.0%
$38.00
+76.5%
+48.6%$1.42B$6.13M-7.48138Short Interest ↑
CVAC
CureVac
2.2112 of 5 stars
$6.50
-6.2%
$24.33
+274.4%
-66.4%$1.44B$115.57M0.00455
CINC
CinCor Pharma
1.6839 of 5 stars
$29.06
-0.5%
$46.67
+60.6%
+46.7%$1.27BN/A-1.6815High Trading Volume
TVTX
Travere Therapeutics
2.1489 of 5 stars
$19.60
-3.0%
$32.91
+67.9%
-12.2%$1.27B$212.02M-4.49310Positive News
SNDX
Syndax Pharmaceuticals
2.4368 of 5 stars
$21.46
-7.0%
$33.57
+56.4%
+23.0%$1.47B$139.71M-8.7659
AUPH
Aurinia Pharmaceuticals
1.6611 of 5 stars
$8.74
-5.1%
$12.50
+43.0%
-11.0%$1.25B$134.03M-11.50300Short Interest ↑
ARVN
Arvinas
2.0021 of 5 stars
$27.68
-5.0%
$68.75
+148.4%
-59.3%$1.47B$131.40M-5.20280
VRNA
Verona Pharma
1.9876 of 5 stars
$19.51
-0.5%
$29.33
+50.4%
+300.4%$1.48B$460,000.00-17.4224
DICE
DICE Therapeutics
1.8553 of 5 stars
$26.05
-1.9%
$65.86
+152.8%
+76.3%$1.24B$1.13M-12.1746Insider Buying
Short Interest ↑
Gap Up
This page (NASDAQ:RCKT) was last updated on 3/29/2023 by MarketBeat.com Staff